Clinical Trial Detail

NCT ID NCT02703272
Title A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications

non-Hodgkin lymphoma

Therapies

Ibrutinib

Carboplatin + Dexamethasone + Etoposide + Ifosfamide + Rituximab

Carboplatin + Dexamethasone + Idarubicin + Ifosfamide + Rituximab + Vincristine Sulfate

Age Groups: child adult

No variant requirements are available.